In the overall study population chemotherapy combined with trastuzumab significantly improved in breast pCR rate to 43% and event-free survival (EFS) in patients with HER2+ breast cancer hazard ratio of 0.59, 95%CI 0.38-0.90; p = 0.013. Here, ERBB2 is linked to breast carcinoma.